Skip to content
Health

FDA Requires Vision Risk Warnings on GLP-1 Weight Loss and Diabetes Drugs

Federal health regulators are mandating label updates to inform patients about a rare eye condition linked to medications like Ozempic and Wegovy.

By 2 min read

The United States Food and Drug Administration (FDA) is requiring manufacturers of popular diabetes and weight-loss drugs, including Ozempic and Wegovy, to add new warnings to their product labels regarding a rare eye condition that can cause permanent vision loss. The regulatory action follows safety reviews concerning a serious medical disorder known as non-arteritic anterior ischemic optic neuropathy (NAION).

NAION is a rare medical condition that restricts blood flow to the front part of the optic nerve, which carries visual signals from the eye to the brain. According to federal warnings and medical experts, the resulting damage typically leads to a sudden, painless loss of vision, usually affecting only one eye. While the condition is very uncommon, health authorities stress the importance of informing patients about the potential risks.

The FDA directive does not order a recall or a suspension of the medications, nor does it mandate that patients stop taking their treatments. Instead, the agency requires pharmaceutical companies to include information about NAION in the warnings and precautions sections of their labels so that consumers and healthcare providers can make well-informed decisions.

A study published in JAMA Ophthalmology analyzed medical records and found a higher prevalence of the condition among patients prescribed semaglutida treatments compared to those receiving other medications. The research observed approximately 6.4 cases per 100,000 patient-years in individuals treated with GLP-1 medications, compared to 3.8 cases per 100,000 patient-years in comparison groups.

The warning applies broadly across the family of GLP-1 receptor agonists and related treatments. Medications impacted by the updated labeling requirements include Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, Trulicity, Rybelsus, Soliqua, Xultophy, Byetta, and Foundayo.

Medical professionals note that patients with pre-existing health issues face a higher baseline vulnerability to optic nerve disorders. Established risk factors include diabetes, high blood pressure, cigarette smoking, sleep apnea, anemia, and kidney disease. Experts advise individuals considering these treatments to consult their physicians and undergo comprehensive eye evaluations, particularly if they have a history of ocular complications.

Health authorities strongly advise consumers against altering dosages or discontinuing prescribed medications independently. Abruptly stopping a treatment without medical supervision can severely disrupt the management of chronic conditions such as type 2 diabetes or obesity. Patients experiencing sudden vision changes, blurriness, or blind spots are urged to seek immediate medical attention.

Sources

Related stories